Hudis et al. conducted a phase I study to investigate the antitumoral activity of Trastuzumab (HER2 inhibitor) and MK-2206 (AKT 1 and AKT2 inhibitor) in patients with GC. This evidence concerns the gene AKT1 and gastric cancer.